183669-13-8

Basic information

• Product Name: Carbamic acid, [1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 183669-13-8
• Molecular Formula: C14H20N2O5
• Molecular Weight: 296.323
• Mol File: 183669-13-8.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester(183669-13-8)
• EPA Substance Registry System: Carbamic acid, [1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]-, 1,1-dimethylethyl ester(183669-13-8)

Safety Data

• Hazardous Substances Data: 183669-13-8(Hazardous Substances Data)

Upstream product

• 89288-22-2 2-amino-3-(4-nitrophenyl)propan-1-ol 
• 74651-77-7 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 86937-80-6 2-tert-butoxycarbonylamino-3-(4-nitro-phenyl)-propionic acid 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 1005484-22-9 toluene-4-sulfonic acid 2-tert-butoxycarbonylamino-3-(4-nitrophenyl)propyl ester 
• 1258945-86-6 tert-butyl N-[1-(4-nitrophenyl)-3-oxopropan-2-yl]carbamate 
• 1258945-87-7 1,4,7-tri-tert-butyl 10-(2-{[(tert-butoxy)carbonyl]amino}-3-[4-(nitro)phenyl]propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate 
• 1005484-24-1 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate 

Relevant articles and documents

ALIPHATIC PROLINAMIDE DERIVATIVES

This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy

An antibody-targeted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand that can effectively hold a cytotoxic metal with clinically acceptable complexation kinetics and stability while being attached to a tumor-specific antibody. Clinical exploration of the therapeutic potential of RIT has been challenged by the absence of adequate ligand, a critical component for enhancing the efficacy of the cancer therapy. To address this deficiency, the bifunctional ligand C-NETA in a unique structural class possessing both a macrocyclic cavity and a flexible acyclic moiety was designed. The practical, reproducible, and readily scalable synthetic route to C-NETA was developed, and its potential as the chelator of 212Bi, 213Bi, and 177Lu for RIT was evaluated in vitro and in vivo. C-NETA rapidly binds both Lu(III) and Bi(III), and the respective metal complexes remain extremely stable in serum for 14 days. 177Lu-C-NETA and 205/6Bi-C-NETA possess an excellent or acceptable in vivo biodistribution profile.